Asylsuchende und Flüchtlinge in der Notfallstation

Zusammenfassung: Die vorliegende Querschnittsstudie beschreibt den Gesundheitszustand und die Gesundheitsversorgung von Asylsuchenden und Flüchtlingen aus der Sicht der in der Notfallstation des Kantonsspitals St. Gallen tätigen Ärzte. Die Datenerhebung erfolgte mit Fragebogen und der Dokumentation der Konsultationen von Asylsuchenden/Flüchtlingen und Vergleichspatienten während des elfwöchigen Untersuchungszeitraumes (je 98 Konsultationen entsprechend 3% der während der Studienperiode behandelten Notfälle). 76% dieser Konsultationen betrafen Patienten aus Ex-und Rest-Jugoslawien. Bezüglich der ICD-codierten Hauptdiagnosen war nach Alterskorrektur kein Unterschied zwischen Asylsuchenden/Flüchtlingen und der Vergleichsgruppe erkennbar. Im Vergleich zu dem hausärztlichen Patientenklientel überwogen die Verletzungen signifikant (37% vs. 8%). Asylsuchende/Flüchtlinge und die Vergleichsgruppe unterschieden sich nicht signifikant bezüglich der Frequenz, mit der ein Patient als Notfall klassifiziert wurde (58% vs. 65%), ebenso war kein signifikanter Unterschied in der Hospitalisationsrate (29% vs. 36%) festzustellen. Als Notfälle bewertete Konsultationen Wurden häufiger in der Nacht als am Tag registriert. Die Aufenthaltsdauer der Asylsuchenden/Flüchtlinge in der Schweiz war negativ mit der Verfügbarkeit eines Hausarztes und der Klassifikation eines Patienten als Notfall assoziiert. Mangelnde Erfahrung in der Betreuung von Asylsuchenden/Flüchtlingen und das Defizit an Ausbildung und Vertrautheit mit spezifischen administrativen Problemen wurden von den befragten Ärzten als Hauptschwierigkeiten genannt. Für die Verbesserung der Nutzung von Notfallstationen bietet sich an, möglichst frühzeitig die Kenntnisse von Asylsuchenden über das schweizerische Gesundheitswesen zu fördern und eine hausärztliche Betreuung in die Wege zu leite

A bottom-up quantification of foliar mercury uptake fluxes across Europe

The exchange of gaseous elemental mercury, Hg(0), between the atmosphere and terrestrial surfaces remains poorly understood mainly due to difficulties in measuring net Hg(0) fluxes on the ecosystem scale. Emerging evidence suggests foliar uptake of atmospheric Hg(0) to be a major deposition pathway to terrestrial surfaces. Here, we present a bottom-up approach to calculate Hg(0) uptake fluxes to aboveground foliage by combining foliar Hg uptake rates normalized to leaf area with species-specific leaf area indices. This bottom-up approach incorporates systematic variations in crown height and needle age. We analyzed Hg content in 583 foliage samples from six tree species at 10 European forested research sites along a latitudinal gradient from Switzerland to northern Finland over the course of the 2018 growing season. Foliar Hg concentrations increased over time in all six tree species at all sites. We found that foliar Hg uptake rates normalized to leaf area were highest at the top of the tree crown. Foliar Hg uptake rates decreased with needle age of multiyear-old conifers (spruce and pine). Average species-specific foliar Hg uptake fluxes during the 2018 growing season were 18 ± 3 µg Hg m−2 for beech, 26 ± 5 µg Hg m−2 for oak, 4 ± 1 µg Hg m−2 for pine and 11 ± 1 µg Hg m−2 for spruce. For comparison, the average Hg(II) wet deposition flux measured at 5 of the 10 research sites during the same period was 2.3 ± 0.3 µg Hg m−2, which was 4 times lower than the site-averaged foliar uptake flux of 10 ± 3 µg Hg m−2. Scaling up site-specific foliar uptake rates to the forested area of Europe resulted in a total foliar Hg uptake flux of approximately 20 ± 3 Mg during the 2018 growing season. Considering that the same flux applies to the global land area of temperate forests, we estimate a foliar Hg uptake flux of 108 ± 18 Mg. Our data indicate that foliar Hg uptake is a major deposition pathway to terrestrial surfaces in Europe. The bottom-up approach provides a promising method to quantify foliar Hg uptake fluxes on an ecosystem scale

Thrombin Generation Is Associated with Venous Thromboembolism Recurrence, but Not with Major Bleeding and Death in the Elderly: A Prospective Multicenter Cohort Study

It is currently unknown whether thrombin generation is associated with venous thromboembolism (VTE) recurrence, major bleeding, or mortality in the elderly. Therefore, our aim was to prospectively study the association between thrombin generation and VTE recurrence, major bleeding, and mortality in elderly patients with acute VTE. Consecutive patients aged ≥65 years with acute VTE were followed for 2 years, starting from 1 year after the index VTE. Primary outcomes were VTE recurrence, major bleeding, and mortality. Thrombin generation was assessed in 551 patients 1 year after the index VTE. At this time, 59% of the patients were still anticoagulated. Thrombin generation was discriminatory for VTE recurrence, but not for major bleeding and mortality in non-anticoagulated patients. Moreover, peak ratio (adjusted subhazard ratio 4.09, 95% CI, 1.12-14.92) and normalized peak ratio (adjusted subhazard ratio 2.18, 95% CI, 1.28-3.73) in the presence/absence of thrombomodulin were associated with VTE recurrence, but not with major bleeding and mortality after adjustment for potential confounding factors. In elderly patients, thrombin generation was associated with VTE recurrence, but not with major bleeding and/or mortality. Therefore, our study suggests the potential usefulness of thrombin generation measurement after anticoagulation completion for VTE to help identify among elderly patients those at higher risk of VTE recurrence

A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial

BACKGROUND: Tobacco dependence is the leading cause of preventable death and disabilities worldwide and nicotine is the main substance responsible for the addiction to tobacco. A vaccine against nicotine was tested in a 6-month randomized, double blind phase II smoking cessation study in 341 smokers with a subsequent 6-month follow-up period. METHODOLOGY/PRINCIPAL FINDINGS: 229 subjects were randomized to receive five intramuscular injections of the nicotine vaccine and 112 to receive placebo at monthly intervals. All subjects received individual behavioral smoking cessation counseling. The vaccine was safe, generally well tolerated and highly immunogenic, inducing a 100% antibody responder rate after the first injection. Point prevalence of abstinence at month 2 showed a statistically significant difference between subjects treated with Nicotine-Qbeta (47.2%) and placebo (35.1%) (P = 0.036), but continuous abstinence between months 2 and 6 was not significantly different. However, in subgroup analysis of the per-protocol population, the third of subjects with highest antibody levels showed higher continuous abstinence from month 2 until month 6 (56.6%) than placebo treated participants (31.3%) (OR 2.9; P = 0.004) while medium and low antibody levels did not increase abstinence rates. After 12 month, the difference in continuous abstinence rate between subjects on placebo and those with high antibody response was maintained (difference 20.2%, P = 0.012). CONCLUSIONS: Whereas Nicotine-Qbeta did not significantly increase continuous abstinence rates in the intention-to-treat population, subgroup analyses of the per-protocol population suggest that such a vaccination against nicotine can significantly increase continuous abstinence rates in smokers when sufficiently high antibody levels are achieved. Immunotherapy might open a new avenue to the treatment of nicotine addiction. TRIAL REGISTRATION: Swiss Medical Registry 2003DR2327; ClinicalTrials.gov NCT00369616

The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology

Venous thromboembolism (VTE) is common and has a high impact on morbidity, mortality, and costs of care. Although most of the patients with VTE are aged ≥65years, there is little data about the medical outcomes in the elderly with VTE. The Swiss Cohort of Elderly Patients with VTE (SWITCO65+) is a prospective multicenter cohort study of in- and outpatients aged ≥65years with acute VTE from all five Swiss university and four high-volume non-university hospitals. The goal is to examine which clinical and biological factors and processes of care drive short- and long-term medical outcomes, health-related quality of life, and medical resource utilization in elderly patients with acute VTE. The cohort also includes a large biobank with biological material from each participant. From September 2009 to March 2012, 1,863 elderly patients with VTE were screened and 1003 (53.8%) were enrolled in the cohort. Overall, 51.7% of patients were aged ≥75years and 52.7% were men. By October 16, 2012, after an average follow-up time of 512days, 799 (79.7%) patients were still actively participating. SWITCO65+ is a unique opportunity to study short- and long-term outcomes in elderly patients with VTE. The Steering Committee encourages national and international collaborative research projects related to SWITCO65+, including sharing anonymized data and biological sample

Echocardiography does not predict mortality in hemodynamically stable elderly patients with acute pulmonary embolism.

BACKGROUND The evidence on the prognostic value of transthoracic echocardiography (TTE) in elderly, hemodynamically stable patients with Pulmonary Embolism (PE) is limited. OBJECTIVES To evaluate the prevalence of common echocardiographic signs of right ventricular (RV) dysfunction and their prognostic impact in hemodynamically stable patients aged ≥65years with acute PE in a prospective multicenter cohort. METHODS TTE was performed by cardiologists. We defined RV dysfunction as a RV/left ventricular ratio >0.9 or RV hypokinesis (primary definition) or the presence of ≥1 or ≥2 of 6 predefined echocardiographic signs (secondary definitions). Outcomes were overall mortality and mortality/non-fatal recurrent venous thromboembolism (VTE) at 30days, adjusting for the Pulmonary Embolism Severity Index risk score and highly sensitive troponin T values. RESULTS Of 400 patients, 36% had RV dysfunction based on our primary definition, and 81% (≥1 sign) and 53% (≥2 signs) based on our secondary definitions, respectively. Using our primary definition, there was no association between RV dysfunction and mortality (adjusted HR 0.90, 95% CI 0.31-2.58) and mortality/non-fatal VTE (adjusted HR 1.09, 95% CI 0.40-2.98). Similarly, there was no statistically significant association between the presence of ≥1 or ≥2 echocardiographic signs (secondary definitions) and clinical outcomes. CONCLUSION The prevalence of echocardiographic RV dysfunction varied widely depending upon the definition used. There was no association between RV dysfunction and clinical outcomes. Thus, TTE may not be suitable as a stand-alone risk assessment tool in elderly patients with acute PE. CLINICAL TRIAL REGISTRATION http://clinicaltrials.gov. Identifier: NCT00973596